tranexamic acid has been researched along with Hemorrhagic Shock in 64 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Because no medication has been approved for coagulation support in trauma, the current study was aimed to evaluate the effectiveness of intravenous injection of Tranexamic acid (TXA) in patients with acute traumatic bleeding." | 9.41 | The effect of early tranexamic acid on bleeding, blood product consumption, mortality and length of hospital stay in trauma cases with hemorrhagic shock: a randomized clinical trial. ( Alimohamadi, Y; Khaleghian, M; Negahi, A; Teimoury, T; Vaziri, M, 2021) |
| " Tranexamic acid was associated with a higher rate of distal embolism in those who received REBOA, regardless of access sheath size." | 8.31 | Use of Tranexamic Acid With Resuscitative Endovascular Balloon Occlusion of the Aorta is Associated With Higher Distal Embolism Rates: Results From the American Association of Surgery for Trauma Aortic Occlusion and Resuscitation for Trauma and Acute Care ( Brenner, M; Coimbra, R; Dennis, B; Kundi, R; Moore, E; Moore, L; Romagnoli, A; Sauaia, A; Scalea, T; Shaw, J; Teeter, W; Zakhary, B, 2023) |
| "Improved outcomes with early tranexamic acid (TXA) following trauma hemorrhagic shock (T/HS) may be related to its antifibrinolytic, as well as anti-inflammatory properties." | 8.12 | The effect of tranexamic acid dosing regimen on trauma/hemorrhagic shock-related glycocalyx degradation and endothelial barrier permeability: An in vitro model. ( Carge, M; Diebel, LN; Liberati, DM, 2022) |
| "Early intravenous administration of tranexamic acid has been shown to protect the intestinal barrier after a model of trauma-hemorrhagic shock in the rat, but the potential mechanism remains unclear." | 7.96 | Early intravenous administration of tranexamic acid ameliorates intestinal barrier injury induced by neutrophil extracellular traps in a rat model of trauma/hemorrhagic shock. ( Chu, C; Ding, W; Duan, Z; Li, J; Liu, B; Sun, S; Wang, K; Wang, X; Xie, T; Yang, C, 2020) |
| "Tranexamic acid (TXA) improves survival in traumatic hemorrhage, but difficulty obtaining intravenous (IV) access may limit its use in austere environments, given its incompatibility with blood products." | 7.96 | Pharmacokinetics of Tranexamic Acid Given as an Intramuscular Injection Compared to Intravenous Infusion in a Swine Model of Ongoing Hemorrhage. ( Beyer, CA; Caples, CM; DeSoucy, ES; Grayson, JK; Hoareau, GL; Johnson, MA; Kashtan, HW; Spruce, MW, 2020) |
| "Intravenous (IV) tranexamic acid (TXA) is an adjunct for resuscitation in hemorrhagic shock; however, IV access in these patients may be difficult or impossible." | 7.91 | Pharmacokinetics of Tranexamic Acid via Intravenous, Intraosseous, and Intramuscular Routes in a Porcine (Sus scrofa) Hemorrhagic Shock Model. ( Davidson, AJ; DeSoucy, ES; Ferencz, SE; Galante, JM; Grayson, JK; Hoareau, GL; Simon, MA; Tibbits, EM, 2019) |
| "It has been demonstrated that tranexamic acid (TXA), a synthetic derivative of lysine, alleviates lung damage in a trauma-hemorrhagic shock (T/HS) model." | 7.88 | Anti-inflammatory effect of tranexamic acid against trauma-hemorrhagic shock-induced acute lung injury in rats. ( Feng, C; Gao, Y; Jin, H; Li, T; Liu, Y; Teng, Y, 2018) |
| "The California Prehospital Antifibrinolytic Therapy (Cal-PAT) study seeks to assess the safety and impact on patient mortality of tranexamic acid (TXA) administration in cases of trauma-induced hemorrhagic shock." | 7.85 | Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study. ( Benson, P; Borger, R; Culhane, JT; Dong, F; Jabourian, A; Jabourian, N; Kissel, S; Kwong, E; Ludi, D; Mistry, J; Neeki, MM; O'Bosky, KR; Pennington, TW; Pitts, R; Powell, J; Schulz-Costello, K; Seiler, K; Sporer, K; Surrusco, MS; Toy, J; Vaezazizi, R; Van Stralen, D; Vara, R; Wong, D; Yoshida-McMath, C, 2017) |
| "Results from this study demonstrate that experimental hemorrhagic shock leads to decreased response to the α1-selective agonist phenylephrine and decreased α1 receptor density via circulating shock factors." | 7.85 | Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock. ( Aletti, F; Chang, M; Kistler, EB; Leon, J; Li, JB; Santamaria, MH; Schmid-Schönbein, GW; Tan, A, 2017) |
| "Intravenous tranexamic acid (TXA) is an effective adjunct after hemorrhagic shock (HS) because of its antifibrinolytic properties." | 7.83 | Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock. ( Ban, K; Kozar, RA; LeBlanc, A; Peng, Z, 2016) |
| " He was anticoagulated with dabigatran due to past atrial fibrillation." | 7.80 | Dabigatran anticoagulation and Stanford type A aortic dissection: lethal coincidence: Case report with literature review. ( Bettex, D; Bosshart, M; Brand, B; Schlicker, A; Spahn, DR; Stein, P, 2014) |
| "We hypothesized that trauma patients in hemorrhagic shock with hyperfibrinolysis on thromboelastography (TEG) LY30 would have increased complement activation at early time points, as measured by soluble C5b-9 complex, and TXA would prevent this." | 5.56 | Tranexamic acid is associated with reduced complement activation in trauma patients with hemorrhagic shock and hyperfibrinolysis on thromboelastography. ( Barrett, CD; Chandler, J; Ghasabyan, A; Moore, EE; Moore, HB; Vigneshwar, N; Yaffe, MB, 2020) |
| "The mechanisms for cardiac injury after hemorrhagic shock (HS) are unresolved." | 5.51 | Enteral Tranexamic Acid Decreases Proteolytic Activity in the Heart in Acute Experimental Hemorrhagic Shock. ( Aletti, F; Chin, K; Kistler, EB; Mazor, R; Santamaria, M, 2019) |
| "Controlled hemorrhagic shock was induced in adult Sprague Dawley rats to a mean arterial pressure of 30 mmHg." | 5.48 | Tranexamic acid decreases rodent hemorrhagic shock-induced inflammation with mixed end-organ effects. ( Bradley, MJ; Davis, TA; Foster, AD; Rothberg, PA; Walker, PF, 2018) |
| "After the addition of hemorrhagic shock and resuscitation to TBI, TXA administration still did not affect coagulation parameters, systemic or cerebral inflammation, or platelet activation, as compared with saline alone." | 5.46 | Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage. ( Boudreau, RM; Caldwell, CC; Friend, LA; Goetzman, H; Goodman, MD; Johnson, M; Makley, AT; Pritts, TA; Veile, R, 2017) |
| "Because no medication has been approved for coagulation support in trauma, the current study was aimed to evaluate the effectiveness of intravenous injection of Tranexamic acid (TXA) in patients with acute traumatic bleeding." | 5.41 | The effect of early tranexamic acid on bleeding, blood product consumption, mortality and length of hospital stay in trauma cases with hemorrhagic shock: a randomized clinical trial. ( Alimohamadi, Y; Khaleghian, M; Negahi, A; Teimoury, T; Vaziri, M, 2021) |
| " Tranexamic acid was associated with a higher rate of distal embolism in those who received REBOA, regardless of access sheath size." | 4.31 | Use of Tranexamic Acid With Resuscitative Endovascular Balloon Occlusion of the Aorta is Associated With Higher Distal Embolism Rates: Results From the American Association of Surgery for Trauma Aortic Occlusion and Resuscitation for Trauma and Acute Care ( Brenner, M; Coimbra, R; Dennis, B; Kundi, R; Moore, E; Moore, L; Romagnoli, A; Sauaia, A; Scalea, T; Shaw, J; Teeter, W; Zakhary, B, 2023) |
| "Tranexamic acid (TXA) has shown to be beneficial in selected patients with hemorrhagic shock." | 4.12 | The effect of prehospital tranexamic acid on outcome in polytrauma patients with associated severe brain injury. ( Jochems, D; Leenen, LPH; van Wessem, KJP, 2022) |
| "Tranexamic acid (TXA) improves survival in traumatic hemorrhage, but difficulty obtaining intravenous (IV) access may limit its use in austere environments, given its incompatibility with blood products." | 3.96 | Pharmacokinetics of Tranexamic Acid Given as an Intramuscular Injection Compared to Intravenous Infusion in a Swine Model of Ongoing Hemorrhage. ( Beyer, CA; Caples, CM; DeSoucy, ES; Grayson, JK; Hoareau, GL; Johnson, MA; Kashtan, HW; Spruce, MW, 2020) |
| "Early intravenous administration of tranexamic acid has been shown to protect the intestinal barrier after a model of trauma-hemorrhagic shock in the rat, but the potential mechanism remains unclear." | 3.96 | Early intravenous administration of tranexamic acid ameliorates intestinal barrier injury induced by neutrophil extracellular traps in a rat model of trauma/hemorrhagic shock. ( Chu, C; Ding, W; Duan, Z; Li, J; Liu, B; Sun, S; Wang, K; Wang, X; Xie, T; Yang, C, 2020) |
| "Intravenous (IV) tranexamic acid (TXA) is an adjunct for resuscitation in hemorrhagic shock; however, IV access in these patients may be difficult or impossible." | 3.91 | Pharmacokinetics of Tranexamic Acid via Intravenous, Intraosseous, and Intramuscular Routes in a Porcine (Sus scrofa) Hemorrhagic Shock Model. ( Davidson, AJ; DeSoucy, ES; Ferencz, SE; Galante, JM; Grayson, JK; Hoareau, GL; Simon, MA; Tibbits, EM, 2019) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent shown to reduce morbidity and mortality in hemorrhagic shock." | 3.91 | Effect of Fluctuating Extreme Temperatures on Tranexamic Acid. ( Acquisto, NM; Cushman, JT; Davis, H; Estephan, M; Loner, C, 2019) |
| " The California Prehospital Antifibrinolytic Therapy (Cal-PAT) study seeks to evaluate the safety and efficacy of tranexamic acid (TXA) use in the civilian prehospital setting in cases of traumatic hemorrhagic shock." | 3.88 | Tranexamic Acid in Civilian Trauma Care in the California Prehospital Antifibrinolytic Therapy Study. ( Borger, R; Burgett-Moreno, M; Dong, F; Jabourian, A; Kissel, S; Kwong, E; Lee, T; Ludi, D; Luo-Owen, X; Mousselli, M; Neeki, MM; Niknafs, N; O'Bosky, KR; Pennington, T; Powell, J; Rabiei, M; Sporer, K; Toy, J; Vaezazizi, R; Vara, R; Wong, D, 2018) |
| "It has been demonstrated that tranexamic acid (TXA), a synthetic derivative of lysine, alleviates lung damage in a trauma-hemorrhagic shock (T/HS) model." | 3.88 | Anti-inflammatory effect of tranexamic acid against trauma-hemorrhagic shock-induced acute lung injury in rats. ( Feng, C; Gao, Y; Jin, H; Li, T; Liu, Y; Teng, Y, 2018) |
| "The use of TXA in the treatment of traumatic bleeding has the potential to prevent many premature deaths every year." | 3.86 | Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. ( Edwards, P; Ker, K; Kiriya, J; Perel, P; Roberts, I; Shakur, H, 2012) |
| "The California Prehospital Antifibrinolytic Therapy (Cal-PAT) study seeks to assess the safety and impact on patient mortality of tranexamic acid (TXA) administration in cases of trauma-induced hemorrhagic shock." | 3.85 | Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study. ( Benson, P; Borger, R; Culhane, JT; Dong, F; Jabourian, A; Jabourian, N; Kissel, S; Kwong, E; Ludi, D; Mistry, J; Neeki, MM; O'Bosky, KR; Pennington, TW; Pitts, R; Powell, J; Schulz-Costello, K; Seiler, K; Sporer, K; Surrusco, MS; Toy, J; Vaezazizi, R; Van Stralen, D; Vara, R; Wong, D; Yoshida-McMath, C, 2017) |
| "Results from this study demonstrate that experimental hemorrhagic shock leads to decreased response to the α1-selective agonist phenylephrine and decreased α1 receptor density via circulating shock factors." | 3.85 | Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock. ( Aletti, F; Chang, M; Kistler, EB; Leon, J; Li, JB; Santamaria, MH; Schmid-Schönbein, GW; Tan, A, 2017) |
| "Intravenous tranexamic acid (TXA) is an effective adjunct after hemorrhagic shock (HS) because of its antifibrinolytic properties." | 3.83 | Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock. ( Ban, K; Kozar, RA; LeBlanc, A; Peng, Z, 2016) |
| " He was anticoagulated with dabigatran due to past atrial fibrillation." | 3.80 | Dabigatran anticoagulation and Stanford type A aortic dissection: lethal coincidence: Case report with literature review. ( Bettex, D; Bosshart, M; Brand, B; Schlicker, A; Spahn, DR; Stein, P, 2014) |
| "The evidence gap in mature civilian trauma systems is limiting the widespread use of TXA and its potential benefits on survival." | 2.80 | Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. ( Brohi, K; Cole, E; Davenport, R; Willett, K, 2015) |
| "Trauma is a major source of morbidity and mortality for children worldwide; life-threatening hemorrhage is a primary cause of preventable death." | 2.72 | Hemostatic Resuscitation in Children. ( Leeper, C; Ramos-Jimenez, RG, 2021) |
| "Trauma is a major cause of mortality globally, with post-traumatic hemorrhage being the leading cause of death amongst trauma patients." | 2.66 | Limiting Blood Loss in Orthopaedic Trauma: Strategies and Effects. ( Leighton, JL; Schneider, P; You, D, 2020) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent used to prevent traumatic exsanguination." | 2.66 | The Use of Tranexamic Acid (TXA) for the Management of Hemorrhage in Trauma Patients in the Prehospital Environment: Literature Review and Descriptive Analysis of Principal Themes. ( Jesulola, E; Morris, D; Stansfield, R, 2020) |
| "High-level evidence supports its use in trauma and strongly suggests that its implementation in the prehospital setting offers a survival advantage to many patients, particularly when evacuation to surgical care may be delayed." | 2.52 | Tranexamic acid as part of remote damage-control resuscitation in the prehospital setting: A critical appraisal of the medical literature and available alternatives. ( Ausset, S; Cap, AP; Glassberg, E; Hoffmann, C; Nadler, R; Plang, S; Sailliol, A; Sunde, G, 2015) |
| "Hemorrhage is the leading cause of preventable death after injury." | 1.91 | Time to early resuscitative intervention association with mortality in trauma patients at risk for hemorrhage. ( Brown, JB; Claridge, JA; Daley, BJ; Deeb, AP; Eastridge, BJ; Guyette, FX; Harbrecht, BG; Joseph, B; Miller, RS; Nirula, R; Phelan, HA; Sperry, JL; Vercruysse, GA, 2023) |
| "Traumatic/hemorrhagic shock, sepsis and other inflammatory processes lead to endothelial activation and a loss of the endothelial glycocalyx." | 1.91 | Effect of tranexamic acid on endothelial von Willebrand factor/ADAMTS-13 response to in vitro shock conditions. ( Diebel, LN; Liberati, DM, 2023) |
| "Mice were then subjected to controlled hemorrhagic shock for 1 h to a goal MAP of 25 mmHg." | 1.72 | MULTIMODAL TREATMENT APPROACHES TO COMBINED TRAUMATIC BRAIN INJURY AND HEMORRHAGIC SHOCK ALTER POSTINJURY INFLAMMATORY RESPONSE. ( Baucom, MR; England, LG; Goodman, MD; Pritts, TA; Schuster, RM; Wallen, TE, 2022) |
| "Trauma and hemorrhagic shock (T/HS) is a major cause of morbidity and mortality." | 1.72 | Continuous enteral protease inhibition as a novel treatment for experimental trauma/hemorrhagic shock. ( Aletti, F; DeLano, FA; Kistler, EB; Maffioli, E; Mu, H; Schmid-Schönbein, GW; Tedeschi, G, 2022) |
| "We hypothesized that trauma patients in hemorrhagic shock with hyperfibrinolysis on thromboelastography (TEG) LY30 would have increased complement activation at early time points, as measured by soluble C5b-9 complex, and TXA would prevent this." | 1.56 | Tranexamic acid is associated with reduced complement activation in trauma patients with hemorrhagic shock and hyperfibrinolysis on thromboelastography. ( Barrett, CD; Chandler, J; Ghasabyan, A; Moore, EE; Moore, HB; Vigneshwar, N; Yaffe, MB, 2020) |
| "Patients with trauma-induced coagulopathies may benefit from the use of antifibrinolytic agents, such as tranexamic acid (TXA)." | 1.56 | Safety and Efficacy of Hospital Utilization of Tranexamic Acid in Civilian Adult Trauma Resuscitation. ( Borger, R; Chandwani, D; Comunale, ME; Dong, F; Inaba, K; Lowe, A; Neeki, MM; Powell, J; Quispe, J; Rabiei, M; Salameh, J; Toy, J; Vara, R; Wong, D, 2020) |
| "Tranexamic acid (TXA) has been shown to reduce mortality in the treatment of traumatic hemorrhage." | 1.51 | Prehospital Tranexamic Acid Administration During Aeromedical Transport After Injury. ( Boudreau, RM; Day, GM; Deshpande, KK; Goodman, MD; Harger, N; Hinckley, WR; Makley, AT; Pritts, TA, 2019) |
| "The mechanisms for cardiac injury after hemorrhagic shock (HS) are unresolved." | 1.51 | Enteral Tranexamic Acid Decreases Proteolytic Activity in the Heart in Acute Experimental Hemorrhagic Shock. ( Aletti, F; Chin, K; Kistler, EB; Mazor, R; Santamaria, M, 2019) |
| "Controlled hemorrhagic shock was induced in adult Sprague Dawley rats to a mean arterial pressure of 30 mmHg." | 1.48 | Tranexamic acid decreases rodent hemorrhagic shock-induced inflammation with mixed end-organ effects. ( Bradley, MJ; Davis, TA; Foster, AD; Rothberg, PA; Walker, PF, 2018) |
| "He was presented in hemorrhagic shock, with an initial lactate of 10." | 1.48 | Hyperfibrinolysis diagnosed with rotational thromboelastometry and treated with tranexamic acid in a dog with acute traumatic coagulopathy. ( Muri, B; Schmierer, P; Schwarz, A; Sigrist, N, 2018) |
| "After the addition of hemorrhagic shock and resuscitation to TBI, TXA administration still did not affect coagulation parameters, systemic or cerebral inflammation, or platelet activation, as compared with saline alone." | 1.46 | Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage. ( Boudreau, RM; Caldwell, CC; Friend, LA; Goetzman, H; Goodman, MD; Johnson, M; Makley, AT; Pritts, TA; Veile, R, 2017) |
| "Hemorrhagic shock is associated with metabolic defects, including hyperglycemia and insulin resistance, but the mechanisms are unknown." | 1.40 | Pancreatic digestive enzyme blockade in the small intestine prevents insulin resistance in hemorrhagic shock. ( DeLano, FA; Schmid-Schönbein, GW, 2014) |
| "Tranexamic acid (TXA) is an antifibrinolytic with anti-inflammatory properties associated with improved outcomes when administered to trauma patients at risk for bleeding; however, its efficacy is unknown in acidemia." | 1.40 | Tranexamic acid corrects fibrinolysis in the presence of acidemia in a swine model of severe ischemic reperfusion. ( DeBarros, M; DuBose, J; Eckert, M; Hatch, Q; Izenberg, S; Martin, M; Porta, CR; Salgar, S, 2014) |
| "Hemorrhagic shock is an emergency, which may benefit from a medicalized prehospital care." | 1.40 | [Out-of-hospital equipment of emergency medical services for hemorrhagic shock management: can do better!]. ( Bounes, V; Ducassé, JL; Lapostolle, F; Minville, V; Vardon, F, 2014) |
| "It is present in 2-8% of trauma patients and associated with shock and increased mortality." | 1.37 | [Hyperfibrinolysis as the cause of haemorrhage and increased mortality in trauma patients]. ( Afshari, A; Johansson, PI; Stensballe, J; Wikkelsø, AJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.56) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 40 (62.50) | 24.3611 |
| 2020's | 23 (35.94) | 2.80 |
| Authors | Studies |
|---|---|
| Ramos-Jimenez, RG | 1 |
| Leeper, C | 1 |
| van Wessem, KJP | 1 |
| Jochems, D | 1 |
| Leenen, LPH | 1 |
| Carge, M | 1 |
| Diebel, LN | 4 |
| Liberati, DM | 4 |
| Negahi, A | 1 |
| Teimoury, T | 1 |
| Alimohamadi, Y | 1 |
| Vaziri, M | 1 |
| Khaleghian, M | 1 |
| Dos Santos, F | 1 |
| Li, JB | 2 |
| Mazor, R | 2 |
| Aletti, F | 4 |
| Kistler, EB | 4 |
| Wallen, TE | 1 |
| Baucom, MR | 1 |
| England, LG | 1 |
| Schuster, RM | 1 |
| Pritts, TA | 3 |
| Goodman, MD | 3 |
| Deeb, AP | 1 |
| Guyette, FX | 1 |
| Daley, BJ | 1 |
| Miller, RS | 1 |
| Harbrecht, BG | 1 |
| Claridge, JA | 1 |
| Phelan, HA | 1 |
| Eastridge, BJ | 1 |
| Joseph, B | 2 |
| Nirula, R | 2 |
| Vercruysse, GA | 2 |
| Sperry, JL | 2 |
| Brown, JB | 1 |
| Harris, E | 1 |
| Shaw, J | 1 |
| Zakhary, B | 1 |
| Coimbra, R | 1 |
| Moore, L | 1 |
| Scalea, T | 1 |
| Kundi, R | 1 |
| Teeter, W | 1 |
| Romagnoli, A | 1 |
| Moore, E | 1 |
| Sauaia, A | 1 |
| Dennis, B | 1 |
| Brenner, M | 1 |
| Lynghaug, T | 1 |
| Bakke, HK | 1 |
| Fuskevåg, OM | 1 |
| Nielsen, EW | 1 |
| Dietrichs, ES | 1 |
| Spruce, MW | 1 |
| Beyer, CA | 1 |
| Caples, CM | 1 |
| DeSoucy, ES | 2 |
| Kashtan, HW | 1 |
| Hoareau, GL | 2 |
| Grayson, JK | 2 |
| Johnson, MA | 1 |
| Richards, JE | 1 |
| Samet, RE | 1 |
| Koerner, AK | 1 |
| Grissom, TE | 1 |
| Chu, C | 1 |
| Yang, C | 1 |
| Wang, X | 1 |
| Xie, T | 1 |
| Sun, S | 1 |
| Liu, B | 1 |
| Wang, K | 1 |
| Duan, Z | 1 |
| Ding, W | 1 |
| Li, J | 1 |
| Davidson, AJ | 1 |
| Simon, MA | 1 |
| Tibbits, EM | 1 |
| Ferencz, SE | 1 |
| Galante, JM | 1 |
| Stansfield, R | 1 |
| Morris, D | 1 |
| Jesulola, E | 1 |
| Neeki, MM | 3 |
| Dong, F | 3 |
| Toy, J | 3 |
| Salameh, J | 1 |
| Rabiei, M | 2 |
| Powell, J | 4 |
| Vara, R | 3 |
| Inaba, K | 2 |
| Wong, D | 3 |
| Comunale, ME | 1 |
| Lowe, A | 1 |
| Chandwani, D | 1 |
| Quispe, J | 1 |
| Borger, R | 3 |
| Leighton, JL | 1 |
| You, D | 1 |
| Schneider, P | 1 |
| Barrett, CD | 1 |
| Vigneshwar, N | 1 |
| Moore, HB | 1 |
| Ghasabyan, A | 1 |
| Chandler, J | 1 |
| Moore, EE | 1 |
| Yaffe, MB | 1 |
| Farrell, MS | 1 |
| Kim, WC | 1 |
| Stein, DM | 1 |
| DeLano, FA | 2 |
| Maffioli, E | 1 |
| Mu, H | 1 |
| Schmid-Schönbein, GW | 3 |
| Tedeschi, G | 1 |
| Nadler, R | 3 |
| Tsur, AM | 1 |
| Lipsky, AM | 2 |
| Benov, A | 1 |
| Sorkin, A | 1 |
| Glassberg, E | 3 |
| Chen, J | 1 |
| Duchesne, J | 1 |
| Taghavi, S | 1 |
| Ninokawa, S | 1 |
| Harris, C | 1 |
| Schroll, R | 1 |
| McGrew, P | 1 |
| McGinness, C | 1 |
| Reily, R | 1 |
| Guidry, C | 1 |
| Tatum, D | 1 |
| McGuire, SS | 1 |
| Klassen, AB | 1 |
| Mullan, AF | 1 |
| Sztajnkrycer, M | 1 |
| Li, SR | 1 |
| Guyette, F | 1 |
| Brown, J | 1 |
| Zenati, M | 1 |
| Reitz, KM | 1 |
| Eastridge, B | 1 |
| O'Keeffe, T | 1 |
| Neal, MD | 1 |
| Zuckerbraun, BS | 1 |
| Martin, JV | 1 |
| Santamaria, MH | 1 |
| Tan, A | 1 |
| Chang, M | 1 |
| Leon, J | 1 |
| Vaezazizi, R | 2 |
| Jabourian, N | 1 |
| Jabourian, A | 2 |
| Seiler, K | 1 |
| Pennington, TW | 1 |
| Yoshida-McMath, C | 1 |
| Kissel, S | 2 |
| Schulz-Costello, K | 1 |
| Mistry, J | 1 |
| Surrusco, MS | 1 |
| O'Bosky, KR | 2 |
| Van Stralen, D | 1 |
| Ludi, D | 2 |
| Sporer, K | 2 |
| Benson, P | 1 |
| Kwong, E | 2 |
| Pitts, R | 1 |
| Culhane, JT | 1 |
| Boudreau, RM | 2 |
| Johnson, M | 1 |
| Veile, R | 1 |
| Friend, LA | 1 |
| Goetzman, H | 1 |
| Caldwell, CC | 1 |
| Makley, AT | 2 |
| Lallemand, MS | 1 |
| Moe, DM | 1 |
| McClellan, JM | 1 |
| Loughren, M | 1 |
| Marko, S | 2 |
| Eckert, MJ | 1 |
| Martin, MJ | 2 |
| Teng, Y | 1 |
| Feng, C | 1 |
| Liu, Y | 1 |
| Jin, H | 1 |
| Gao, Y | 1 |
| Li, T | 1 |
| Muri, B | 1 |
| Schmierer, P | 1 |
| Schwarz, A | 1 |
| Sigrist, N | 1 |
| Kuckelman, J | 1 |
| Barron, M | 1 |
| Moe, D | 1 |
| Lallemand, M | 1 |
| McClellan, J | 1 |
| Eckert, M | 2 |
| Chico Fernández, M | 1 |
| Mudarra Reche, C | 1 |
| Mousselli, M | 1 |
| Niknafs, N | 1 |
| Burgett-Moreno, M | 1 |
| Luo-Owen, X | 1 |
| Pennington, T | 1 |
| Lee, T | 1 |
| Walker, PF | 1 |
| Foster, AD | 1 |
| Rothberg, PA | 1 |
| Davis, TA | 1 |
| Bradley, MJ | 1 |
| Deshpande, KK | 1 |
| Day, GM | 1 |
| Hinckley, WR | 1 |
| Harger, N | 1 |
| Santamaria, M | 1 |
| Chin, K | 1 |
| Loner, C | 1 |
| Estephan, M | 1 |
| Davis, H | 1 |
| Cushman, JT | 1 |
| Acquisto, NM | 1 |
| Prat, N | 1 |
| Pidcoke, HF | 1 |
| Sailliol, A | 2 |
| Cap, AP | 2 |
| Goodloe, JM | 1 |
| Howerton, DS | 1 |
| McAnallen, D | 1 |
| Reed, H | 1 |
| Abramovich, A | 1 |
| Feinstein, U | 1 |
| Shaked, G | 1 |
| Kreiss, Y | 1 |
| DeBarros, M | 1 |
| Hatch, Q | 1 |
| Porta, CR | 1 |
| Salgar, S | 1 |
| Izenberg, S | 1 |
| DuBose, J | 1 |
| Martin, M | 1 |
| Stein, P | 1 |
| Bosshart, M | 1 |
| Brand, B | 1 |
| Schlicker, A | 1 |
| Spahn, DR | 1 |
| Bettex, D | 1 |
| Bogert, JN | 1 |
| Harvin, JA | 1 |
| Cotton, BA | 1 |
| Cole, E | 1 |
| Davenport, R | 1 |
| Willett, K | 1 |
| Brohi, K | 1 |
| Vardon, F | 1 |
| Bounes, V | 1 |
| Ducassé, JL | 1 |
| Minville, V | 1 |
| Lapostolle, F | 1 |
| Ausset, S | 2 |
| Sunde, G | 1 |
| Hoffmann, C | 1 |
| Plang, S | 1 |
| Griggs, C | 1 |
| Butler, K | 1 |
| Peng, Z | 1 |
| Ban, K | 1 |
| LeBlanc, A | 1 |
| Kozar, RA | 1 |
| Zentai, C | 1 |
| van der Meijden, PE | 1 |
| Braunschweig, T | 1 |
| Hueck, N | 1 |
| Honickel, M | 1 |
| Spronk, HM | 1 |
| Rossaint, R | 1 |
| Grottke, O | 1 |
| Güven, R | 1 |
| Daniel, Y | 1 |
| Habas, S | 1 |
| Malan, L | 1 |
| Escarment, J | 1 |
| David, JS | 1 |
| Peyrefitte, S | 1 |
| Roy, M | 1 |
| Burggraf, M | 1 |
| Lendemans, S | 1 |
| de Groot, H | 1 |
| Rohrig, R | 1 |
| Diebel, ME | 1 |
| Fritsch, N | 1 |
| Pouquet, O | 1 |
| Roux, B | 1 |
| Abdelmoumen, Y | 1 |
| Janvier, G | 1 |
| Daban, JL | 1 |
| de Saint Maurice, G | 1 |
| Blot, RM | 1 |
| Wikkelsø, AJ | 1 |
| Afshari, A | 1 |
| Stensballe, J | 1 |
| Johansson, PI | 1 |
| Morrison, JJ | 1 |
| Dubose, JJ | 1 |
| Rasmussen, TE | 1 |
| Midwinter, MJ | 1 |
| Fernández-Mondéjar, E | 1 |
| Guerrero-López, F | 1 |
| Ker, K | 1 |
| Kiriya, J | 1 |
| Perel, P | 1 |
| Edwards, P | 1 |
| Shakur, H | 1 |
| Roberts, I | 1 |
| Kuĭian, SM | 1 |
| Pogosov, VS | 1 |
| Kokliaeva, NV | 1 |
| Tiukov, VL | 1 |
| Riazanov, VB | 1 |
| Gur'ianov, VA | 1 |
| Akopian, RG | 1 |
| Daĭkhes, NA | 1 |
| Davudov, KhSh | 1 |
| Nazhmudinov, II | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Safety and Efficacy of the Second Dose of Tranexamic Acid Administration of Trauma Patients: A Randomized, Double-blind Controlled Clinical Trial[NCT03846973] | Phase 3 | 220 participants (Actual) | Interventional | 2018-12-02 | Completed | ||
| Tranexamic Acid in Prehospital and In Hospital Civilian Trauma Care in Antifibrinolytic Therapy Study[NCT03469947] | Phase 3 | 200 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | ||
| TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630] | Phase 3 | 130 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for tranexamic acid and Hemorrhagic Shock
| Article | Year |
|---|---|
Hemostatic Resuscitation in Children.
Topics: Blood Transfusion; Child; Hemostatics; Humans; Resuscitation; Shock, Hemorrhagic; Tranexamic Acid; W | 2021 |
Tranexamic Acid in the Perioperative Period: Yes, No, Maybe?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Dose-Response Relationship, Drug; Humans; Postoperati | 2019 |
The Use of Tranexamic Acid (TXA) for the Management of Hemorrhage in Trauma Patients in the Prehospital Environment: Literature Review and Descriptive Analysis of Principal Themes.
Topics: Antifibrinolytic Agents; Emergency Medical Services; Humans; Shock, Hemorrhagic; Tranexamic Acid; Wo | 2020 |
Limiting Blood Loss in Orthopaedic Trauma: Strategies and Effects.
Topics: Blood Coagulation Disorders; Hemostasis; Humans; Orthopedic Procedures; Resuscitation; Shock, Hemorr | 2020 |
Emergency Transfusions.
Topics: Antifibrinolytic Agents; Blood Grouping and Crossmatching; Blood Transfusion; Catheterization, Centr | 2020 |
[Evolution of US military transfusion support for resuscitation of trauma and hemorrhagic shock].
Topics: Blood Coagulation Disorders; Blood Component Transfusion; Blood Transfusion; Forecasting; Hemostatic | 2013 |
Damage Control Resuscitation.
Topics: Antifibrinolytic Agents; Blood Transfusion; Clinical Protocols; Crystalloid Solutions; Factor VIIa; | 2016 |
Tranexamic acid as part of remote damage-control resuscitation in the prehospital setting: A critical appraisal of the medical literature and available alternatives.
Topics: Antifibrinolytic Agents; Emergency Medical Services; Hemostatics; Humans; Resuscitation; Shock, Hemo | 2015 |
Damage Control and the Open Abdomen: Challenges for the Nonsurgical Intensivist.
Topics: Abdominal Injuries; Abdominal Wound Closure Techniques; Antifibrinolytic Agents; Blood Transfusion; | 2016 |
Tactical damage control resuscitation in austere military environments.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Component Tra | 2016 |
Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial.
Topics: Antifibrinolytic Agents; Demography; Emergency Treatment; Global Health; Humans; Risk Factors; Shock | 2012 |
4 trials available for tranexamic acid and Hemorrhagic Shock
| Article | Year |
|---|---|
The effect of early tranexamic acid on bleeding, blood product consumption, mortality and length of hospital stay in trauma cases with hemorrhagic shock: a randomized clinical trial.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Length of Stay; Shock, Hemorrhagic; Tranexamic Acid | 2021 |
Early Prehospital Tranexamic Acid Following Injury Is Associated With a 30-day Survival Benefit: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Double-Blind Method; Emergency Medical Services; | 2021 |
Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Drug Administration Schedule; F | 2015 |
Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial.
Topics: Antifibrinolytic Agents; Demography; Emergency Treatment; Global Health; Humans; Risk Factors; Shock | 2012 |
50 other studies available for tranexamic acid and Hemorrhagic Shock
| Article | Year |
|---|---|
The effect of prehospital tranexamic acid on outcome in polytrauma patients with associated severe brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Female; Humans; Male; Middle Age | 2022 |
The effect of tranexamic acid dosing regimen on trauma/hemorrhagic shock-related glycocalyx degradation and endothelial barrier permeability: An in vitro model.
Topics: Antifibrinolytic Agents; Glycocalyx; Humans; Permeability; Shock, Hemorrhagic; Tranexamic Acid | 2022 |
Efficacy of Tranexamic Acid in Blood Versus Crystalloid-Resuscitated Trauma/Hemorrhagic Shock.
Topics: Animals; Blood Pressure; Crystalloid Solutions; Isotonic Solutions; Protease Inhibitors; Rats; Resus | 2022 |
Effect of tranexamic acid on endothelial von Willebrand factor/ADAMTS-13 response to in vitro shock conditions.
Topics: ADAM Proteins; ADAMTS13 Protein; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Huma | 2023 |
MULTIMODAL TREATMENT APPROACHES TO COMBINED TRAUMATIC BRAIN INJURY AND HEMORRHAGIC SHOCK ALTER POSTINJURY INFLAMMATORY RESPONSE.
Topics: Animals; Biomarkers; Brain Injuries; Brain Injuries, Traumatic; Chemokine CCL3; Combined Modality Th | 2022 |
Time to early resuscitative intervention association with mortality in trauma patients at risk for hemorrhage.
Topics: Blood Transfusion; Emergency Medical Services; Hemorrhage; Humans; Resuscitation; Shock, Hemorrhagic | 2023 |
Prehospital Tranexamic Acid Does Not Improve Disability Outcomes.
Topics: Antifibrinolytic Agents; Emergency Medical Services; Humans; Shock, Hemorrhagic; Tranexamic Acid; Tr | 2023 |
Use of Tranexamic Acid With Resuscitative Endovascular Balloon Occlusion of the Aorta is Associated With Higher Distal Embolism Rates: Results From the American Association of Surgery for Trauma Aortic Occlusion and Resuscitation for Trauma and Acute Care
Topics: Adult; Aorta; Balloon Occlusion; Embolism; Endovascular Procedures; Female; Humans; Injury Severity | 2023 |
HOW SHOULD TRANEXAMIC ACID BE ADMINISTERED IN HEMORRHAGIC SHOCK? CONTINUOUS SERUM CONCENTRATION MEASUREMENTS IN A SWINE MODEL.
Topics: Administration, Intravenous; Animals; Antifibrinolytic Agents; Humans; Infusions, Intravenous; Shock | 2023 |
Pharmacokinetics of Tranexamic Acid Given as an Intramuscular Injection Compared to Intravenous Infusion in a Swine Model of Ongoing Hemorrhage.
Topics: Animals; Antifibrinolytic Agents; Disease Models, Animal; Female; Hemorrhage; Infusions, Intravenous | 2020 |
Early intravenous administration of tranexamic acid ameliorates intestinal barrier injury induced by neutrophil extracellular traps in a rat model of trauma/hemorrhagic shock.
Topics: Animals; Antifibrinolytic Agents; Cells, Cultured; Drug Evaluation, Preclinical; Extracellular Traps | 2020 |
Pharmacokinetics of Tranexamic Acid via Intravenous, Intraosseous, and Intramuscular Routes in a Porcine (Sus scrofa) Hemorrhagic Shock Model.
Topics: Administration, Intravenous; Animals; Disease Models, Animal; Humans; Infusions, Intraosseous; Injec | 2019 |
Safety and Efficacy of Hospital Utilization of Tranexamic Acid in Civilian Adult Trauma Resuscitation.
Topics: Adult; Antifibrinolytic Agents; Drug Utilization; Female; Humans; Incidence; Injury Severity Score; | 2020 |
Tranexamic acid is associated with reduced complement activation in trauma patients with hemorrhagic shock and hyperfibrinolysis on thromboelastography.
Topics: Adult; Aged; Antifibrinolytic Agents; Complement Activation; Fibrinolysis; Humans; Male; Middle Aged | 2020 |
Continuous enteral protease inhibition as a novel treatment for experimental trauma/hemorrhagic shock.
Topics: Animals; Disease Models, Animal; Humans; Intestine, Small; Ischemia; Protease Inhibitors; Rats; Rats | 2022 |
Trends in combat casualty care following the publication of clinical practice guidelines.
Topics: Airway Management; Antifibrinolytic Agents; Crystalloid Solutions; Decompression, Surgical; Fluid Th | 2021 |
After 800 Mtp Events, Mortality Due to Hemorrhagic Shock Remains High and Unchanged Despite Several In-Hospital Hemorrhage Control Advancements.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemostatic Techniques; Humans; Louisiana; | 2021 |
A Survey of Tranexamic Acid Use by US Tactical Emergency Medical Support Providers.
Topics: Antifibrinolytic Agents; Emergencies; Humans; Shock, Hemorrhagic; Surveys and Questionnaires; Tranex | 2021 |
Early tranexamic acid administration ameliorates the endotheliopathy of trauma and shock in an in vitro model.
Topics: Angiopoietin-1; Angiopoietin-2; Antifibrinolytic Agents; Cell Adhesion Molecules; Endothelium, Vascu | 2017 |
Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock.
Topics: Animals; Blood Pressure; Disease Models, Animal; Drug Resistance; Fluid Therapy; Hemodynamics; Injec | 2017 |
Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study.
Topics: Adult; Antifibrinolytic Agents; California; Emergency Medical Services; Feasibility Studies; Female; | 2017 |
Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study.
Topics: Adult; Antifibrinolytic Agents; California; Emergency Medical Services; Feasibility Studies; Female; | 2017 |
Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study.
Topics: Adult; Antifibrinolytic Agents; California; Emergency Medical Services; Feasibility Studies; Female; | 2017 |
Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study.
Topics: Adult; Antifibrinolytic Agents; California; Emergency Medical Services; Feasibility Studies; Female; | 2017 |
Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage.
Topics: Animals; Anti-Inflammatory Agents; Antifibrinolytic Agents; Biomarkers; Blood Coagulation Disorders; | 2017 |
No intravenous access, no problem: Intraosseous administration of tranexamic acid is as effective as intravenous in a porcine hemorrhage model.
Topics: Animals; Antifibrinolytic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Infusion | 2018 |
Anti-inflammatory effect of tranexamic acid against trauma-hemorrhagic shock-induced acute lung injury in rats.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Disease Models, | 2018 |
Hyperfibrinolysis diagnosed with rotational thromboelastometry and treated with tranexamic acid in a dog with acute traumatic coagulopathy.
Topics: Accidents, Traffic; Animals; Antifibrinolytic Agents; Blood Coagulation Disorders; Dog Diseases; Dog | 2018 |
Plasma coadministration improves resuscitation with tranexamic acid or prothrombin complex in a porcine hemorrhagic shock model.
Topics: Animals; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Coagulation Tests; Combined M | 2018 |
Traumatic coagulopathies.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Fibrinolysis; Forecasting; Humans; Resuscitati | 2019 |
Tranexamic Acid in Civilian Trauma Care in the California Prehospital Antifibrinolytic Therapy Study.
Topics: Adolescent; Adult; Antifibrinolytic Agents; California; Emergency Medical Services; Female; Glasgow | 2018 |
Tranexamic acid decreases rodent hemorrhagic shock-induced inflammation with mixed end-organ effects.
Topics: Animals; Antifibrinolytic Agents; Inflammation; Lung; Lymph Nodes; Male; Myocardium; Rats, Sprague-D | 2018 |
Prehospital Tranexamic Acid Administration During Aeromedical Transport After Injury.
Topics: Adult; Air Ambulances; Antifibrinolytic Agents; Blood Transfusion; Emergency Service, Hospital; Fema | 2019 |
Enteral Tranexamic Acid Decreases Proteolytic Activity in the Heart in Acute Experimental Hemorrhagic Shock.
Topics: Administration, Oral; Animals; Antifibrinolytic Agents; CD36 Antigens; Disease Models, Animal; Fatty | 2019 |
Effect of Fluctuating Extreme Temperatures on Tranexamic Acid.
Topics: Antifibrinolytic Agents; Cold Temperature; Drug Stability; Emergency Medical Services; Hot Temperatu | 2019 |
How can tranexamic acid help in EMS? TXA offers new hope for an old challenge in traumatic hemorrhagic shock.
Topics: Antifibrinolytic Agents; Emergency Medical Services; Humans; Shock, Hemorrhagic; Shock, Traumatic; T | 2013 |
Tranexamic acid in the prehospital setting: Israel Defense Forces' initial experience.
Topics: Adult; Antifibrinolytic Agents; Clinical Protocols; Emergency Medical Services; Female; Hemorrhage; | 2014 |
Pancreatic digestive enzyme blockade in the small intestine prevents insulin resistance in hemorrhagic shock.
Topics: Animals; Blood Glucose; Glucose Tolerance Test; Insulin Resistance; Intestine, Small; Male; Pancreas | 2014 |
Tranexamic acid corrects fibrinolysis in the presence of acidemia in a swine model of severe ischemic reperfusion.
Topics: Animals; Antifibrinolytic Agents; Disease Models, Animal; Fibrinolysis; Recombinant Proteins; Resusc | 2014 |
Dabigatran anticoagulation and Stanford type A aortic dissection: lethal coincidence: Case report with literature review.
Topics: Aged; Anticoagulants; Aortic Aneurysm, Thoracic; Aortic Dissection; Aortic Valve Insufficiency; Atri | 2014 |
[Out-of-hospital equipment of emergency medical services for hemorrhagic shock management: can do better!].
Topics: Antifibrinolytic Agents; Clinical Protocols; Delphi Technique; Drug Utilization; Emergency Medical S | 2014 |
Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock.
Topics: ADAM17 Protein; Animals; Enzyme-Linked Immunosorbent Assay; Inflammation; Intestinal Mucosa; Intesti | 2016 |
Hemostatic Therapy Using Tranexamic Acid and Coagulation Factor Concentrates in a Model of Traumatic Liver Injury.
Topics: Abdominal Injuries; Animals; Antifibrinolytic Agents; Blood Coagulation; Blood Coagulation Factors; | 2016 |
Treatment of a patient in hemorrhagic shock due to leech bite with tranexamic acid.
Topics: Acne Vulgaris; Antifibrinolytic Agents; Emergency Service, Hospital; Face; Humans; Leeching; Male; S | 2016 |
Tranexamic acid prolongs survival after controlled hemorrhage in rats.
Topics: Animals; Antifibrinolytic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Fibrinolysis | 2017 |
Tranexamic acid and the gut barrier: Protection by inhibition of trypsin uptake and activation of downstream intestinal proteases.
Topics: ADAM17 Protein; Antifibrinolytic Agents; Cell Line; Cells, Cultured; Epithelial Cells; Humans; Inter | 2017 |
[Successful use of recombinant factor VIIa in the control of a massive bleeding in two patients with biventricular assist device (Thoratec)].
Topics: Adult; Anticoagulants; Aprotinin; Blood Transfusion; Blood Transfusion, Autologous; Cardiac Tamponad | 2010 |
Hemostatic agents: which is better?
Topics: Antifibrinolytic Agents; Blood Transfusion; Factor VIIa; France; Hemostatics; Humans; Military Medic | 2010 |
[Hyperfibrinolysis as the cause of haemorrhage and increased mortality in trauma patients].
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Transfusion; Fibrinolysis; Hemorrhage; H | 2011 |
Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study.
Topics: Adolescent; Adult; Afghan Campaign 2001-; Antifibrinolytic Agents; Blast Injuries; Blood Transfusion | 2012 |
Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study.
Topics: Adolescent; Adult; Afghan Campaign 2001-; Antifibrinolytic Agents; Blast Injuries; Blood Transfusion | 2012 |
Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study.
Topics: Adolescent; Adult; Afghan Campaign 2001-; Antifibrinolytic Agents; Blast Injuries; Blood Transfusion | 2012 |
Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study.
Topics: Adolescent; Adult; Afghan Campaign 2001-; Antifibrinolytic Agents; Blast Injuries; Blood Transfusion | 2012 |
Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study.
Topics: Adolescent; Adult; Afghan Campaign 2001-; Antifibrinolytic Agents; Blast Injuries; Blood Transfusion | 2012 |
Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study.
Topics: Adolescent; Adult; Afghan Campaign 2001-; Antifibrinolytic Agents; Blast Injuries; Blood Transfusion | 2012 |
Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study.
Topics: Adolescent; Adult; Afghan Campaign 2001-; Antifibrinolytic Agents; Blast Injuries; Blood Transfusion | 2012 |
Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study.
Topics: Adolescent; Adult; Afghan Campaign 2001-; Antifibrinolytic Agents; Blast Injuries; Blood Transfusion | 2012 |
Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study.
Topics: Adolescent; Adult; Afghan Campaign 2001-; Antifibrinolytic Agents; Blast Injuries; Blood Transfusion | 2012 |
[Secondary prevention in trauma pathology. Is there an influence of commercial interests on evidence implementation?].
Topics: Accident Prevention; Commerce; Decontamination; Diffusion of Innovation; Drug Utilization; Evidence- | 2012 |
Antifibrinolytics in trauma patients: does it MATTER?
Topics: Antifibrinolytic Agents; Female; Humans; Male; Military Personnel; Resuscitation; Shock, Hemorrhagic | 2012 |
[The use of tranexamic acid as an anesthetic component in ENT surgeries in patients with high surgical-anesthetic risk and in hemorrhagic shock intensive therapy].
Topics: Adult; Anesthetics, Local; Antifibrinolytic Agents; Female; Humans; Male; Middle Aged; Risk Factors; | 1999 |